EpCAM (
epithelial cell adhesion molecule) was discovered four decades ago as a
tumor antigen on
colorectal carcinomas. Owing to its frequent and high expression on
carcinomas and their
metastases,
EpCAM serves as a prognostic marker, a therapeutic target, and an anchor molecule on circulating and disseminated
tumor cells (CTCs/DTCs), which are considered the major source for metastatic
cancer cells. Today,
EpCAM is reckoned as a multi-functional transmembrane
protein involved in the regulation of cell adhesion, proliferation, migration, stemness, and epithelial-to-mesenchymal transition (EMT) of
carcinoma cells. To fulfill these functions,
EpCAM is instrumental in intra- and intercellular signaling as a full-length molecule and following regulated intramembrane proteolysis, generating functionally active extra- and intracellular fragments. Intact
EpCAM and its proteolytic fragments interact with
claudins, CD44,
E-cadherin,
epidermal growth factor receptor (EGFR), and intracellular signaling components of the WNT and Ras/Raf pathways, respectively. This plethora of functions contributes to shaping intratumor heterogeneity and partial EMT, which are major determinants of the clinical outcome of
carcinoma patients.
EpCAM represents a marker for the epithelial status of primary and systemic
tumor cells and emerges as a measure for the metastatic capacity of CTCs. Consequentially,
EpCAM has reclaimed potential as a prognostic marker and target on primary and systemic
tumor cells.